Enzymatic synthesis of antibody-human serum albumin conjugate for targeted drug delivery using tyrosinase from Agaricus bisporus by Rollett, Alexandra et al.
Cite this: RSC Advances, 2013, 3,
1460
Enzymatic synthesis of antibody-human serum albumin
conjugate for targeted drug delivery using tyrosinase
from Agaricus bisporus
Received 18th October 2012,
Accepted 21st November 2012
DOI: 10.1039/c2ra22560c
www.rsc.org/advances
Alexandra Rollett,a Barbara Thallinger,a Anna Ohradanova-Repic,b
Christian Machacek,b Evelyn Walenta,c Artur Cavaco-Paulo,d Ruth Birner-
Gruenberger,ef Juliane G. Bogner-Strauss,c Hannes Stockingerb and Georg
M. Guebitz*af
Highly specific targeted drug delivery devices can be obtained with antibody-human serum albumin (mAb-
HSA) conjugates. However, their conventional production involves several reaction steps including
chemical modification and activation of both proteins followed by cross-linking often involving toxic
chemicals. Here, we describe the enzymatic synthesis of mAb-HSA conjugates for targeted drug delivery
devices using tyrosinase from Agaricus bisporus under mild reaction conditions (pH 6.8, 25 uC). Reaction
conditions were optimized by using fluorescence labeled HSA to facilitate SDS-PAGE analysis with
fluorescence scanning. Enzymatic cross-linking in the presence of natural low molecular weight phenolic
compounds (e.g. caffeic acid) resulted in reaction products in the molecular weight range of y216 kDa,
corresponding to mAb-HSA conjugates. The composition of the conjugates was confirmed with tryptic
digestion followed by LC-MS/MS analysis of the resulting peptide fragments. Successful binding of mAb-
HSA conjugates (in contrast to free HSA) to MHC II molecules, located on antigen-presenting cells, was
demonstrated by both ELISA and flow cytometry analysis.
Introduction
Systemic chemotherapy for cancer treatment can often cause
severe side effects where healthy cells and tissues are affected
and destroyed by overdosing drugs or drug accumulation in
normal tissue.1,2 Targeted drug delivery with receptor or ligand
molecules placed on the surface of a delivery device such as
nanoparticles, rendering them recognizable by target cells
would consequently avoid toxicity and collateral damage to
healthy cells. Specific targeting of malignant cells can not only
improve the efficacy of drug delivery but also be exploited for
the development of new diagnostic methods.3
By using antibody-carrier-drug systems the specificity of
antibodies is often exploited to achieve targeting to cancer
cells.4,5 HSA is widely used as a drug carrier6 while more
recently we have described a strategy avoiding toxic chemicals
for the production of HSA-nanoparticles.7 The use of mAb-HSA
drug delivery devices based on this concept is described in the
literature.8–10 The preparation of these mAb-HSA conjugates
involves several reaction steps including the reduction of one
reaction partner to give free thiol groups and the introduction
of maleimide groups to the complementary protein prior to
the actual coupling reaction. These activation steps are
followed by time consuming gel filtration or dialysis. For the
purification of the conjugates another filtration/washing step
is needed.
In this study, we suggest the introduction of an enzyme in
the production of mAb-HSA conjugates. Due to mild reaction
conditions in terms of pH-value, temperature and reaction
environment (i.e. aqueous), enzymes are increasingly used for
the replacement of sometimes even toxic chemicals.11–13
Tyrosinase, for example, was demonstrated to improve the
texture of dough for bread production by oxidation of low
molecular weight phenolic compounds of flour and by cross-
linking of gluten proteins.14 Several research groups used
tyrosinase to produce protein-polysaccharide conjugates to
obtain biomaterials with special mechanical and chemical
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properties.15–17 In the biomedical field tyrosinase cross-linking
was used to enhance the properties of biomaterials: the
antioxidant activity of wool based wound dressings was
increased by 75%, when wool fibres were grafted with
antioxidant phenolic compounds by using tyrosinase.18
Tyrosinase catalyzed cross-linking of collagen was found to
enhance properties important for application in tissue
engineering or as implants.19,20 Here, we present a new
application of tyrosinase based cross-linking in the field of
targeted drug delivery systems.
Tyrosinase is a bifunctional enzyme, catalyzing the o-hydro-
xylation of monophenols and the subsequent oxidation of
o-diphenols to o-quinones [EC 1.10.3.1]. O-quinones are highly
reactive species which undergo non-enzymatic reactions with
amino acid residues containing amino and sulfhydryl groups
such as cysteine or lysine. The degree of cross-linking highly
depends on the accessibility of target amino acids in the
substrate protein. If the substrate is not accepted by the
enzyme due to a very tight structure or due to its size, the use
of low molecular weight compounds (e.g. natural phenolic
molecules), can enable the enzymatic cross-linking as reported
by Thalmann et al.21 The phenolic compounds are oxidized by
tyrosinase and can further react with the amino and sulfhydryl
groups of the protein backbones of larger and less accepted
substrates, such as HSA and monoclonal antibodies (mAbs),
present in solution. Here we tested six different phenolic
compounds for their ability to work as an intermediate
substrate to cross-link HSA and a mouse IgG mAb.
Tyrosinase based cross-linking could be a powerful alter-
native to this conventional strategy. This method not only
shortens expenditure of time but also avoids the use of
expensive and toxic cross-linking chemicals and reducing
reagents, since no preparation of HSA and mAb is necessary
prior to conjugate production.
Results and discussion
Cross-linking
The objective of this work was to investigate the ability of
tyrosinase from Agaricus bisporus (AbT) to cross-link mAb and
HSA for the production of targeted drug delivery systems. No
cross-linking products were found when either free mAb plus
enzyme or free HSA plus enzyme were used, according to SDS-
PAGE analysis. Likewise, when the combination of HSA, mAb
and enzyme was tested, no cross-linking product was found
(Fig. 1). This could be due to limited accessibility of tyrosine
residues within the native proteins. Previously, it has been
reported that due to the opened structure, partially unfolded
proteins were better substrates for T. reesei tyrosinase.22
However, in this study partial unfolding of HSA by using
chaotropic agents or temperature did not lead to cross-linking
products (data not shown). An alternative way to cross-link
proteins using tyrosinase is the addition of natural low
molecular weight phenolic compounds like caffeic acid or
coumaric acid which are suitable substrates for tyrosinase.
These phenolic molecules act as cross-linkers after enzymatic
oxidation to the corresponding o-quinones.21 O-quinones can
Fig. 1 Left: HSA-FITC fluorescence scan; right: Kang staining of SDS PAGE gradient gel (6% lower and 5.5% upper part) showing cross-linking of mAb and HSA by
tyrosinase in combination with different phenolic molecules (lanes 1–6). The arrow marks the mAb-HSA product band at y216 kDa which is found only with CA and
pCA (lane 1 and 2). Lanes 7–15 show references where HSA, phenolic molecules, mAb and AbT were replaced with reaction buffer.
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undergo a spontaneous Michael-like addition with amino- and
sulfhydryl groups of amino acid residues found in the
backbone of proteins21,23 and thereby cross-link proteins.
We tested six different phenolic molecules (caffeic acid (CA),
p-coumaric acid (pCA), guiacol (G), ferulic acid (FA), catechol
(C) and tyrosine (T)) for their ability to serve as cross-linkers
between HSA and mAb. Indeed, new bands above the original
mAb and HSA bands were seen in SDS-PA gels indicating
cross-linking (Fig. 1). For analysis purposes HSA was labeled
covalently with the fluorescent dye fluorescein 5(6)-isothiocya-
nate (FITC) prior to enzymatic coupling reactions. Bands in the
molecular weight range of y216 kDa, visible both in the
fluorescent scan, signaling the presence of HSA (which was
covalently labeled with FITC for analysis) and after Kang
staining can be assigned to mAb-HSA 1 : 1 conjugates. To
verify the composition of the mAb-HSA conjugate, the band
was cut out of the gel and subjected to tryptic digestion
followed by LC-MS/MS analysis. Truly, HSA and mAb were
identified as the most prominent hits in a complete NCBI
protein database search of the conjugate digests peptide mass
patterns (see Table 1). This clearly confirms the nature of the
conjugate and excludes the possibility of artifacts potentially
resulting from HSA oligomers. Analyzing further cross-linking
products, the band at y300 kDa, which is only visible by Kang
staining, can be attributed to mAb-mAb, while the band at
y282 kDa, expectedly visible in fluorescent scans, matches the
predicted molecular weight of HSA-mAb-HSA. Again, no bands
representing HSA-HSA oligomers were detected.
Interestingly, mAb-HSA conjugates were only formed in the
presence of CA and pCA although all 6 linker molecules are
substrates for AbT (data not shown). When comparing the
chemical structures of these molecules, the common struc-
tural elements of CA and pCA are the free hydroxyl groups
located in position 4 for pCA and position 4 and 3 for CA, and
the acrylic acid group in position 1. Also, FA has an acrylic acid
group however, instead of a second hydroxyl group, a methoxy
group is positioned next to the hydroxyl group which can lead
to steric hindrance.23 Another reason for lack of activity with
FA could be, that no further oligomerization is possible after a
5-5 dimerisation of FA, which is the preferred form of linkage
due to lower heat of formation values.24 Looking at G, C and T,
all three molecules do not contain acrylic acid moieties. It
should be mentioned that in contrast to previous findings21 no
difference was found between monophenols and biphenols.
We assume that the structural elements, hydroxyl- and acryl
groups are the key to a successful cross-linking of mAb and
HSA. Further, in absence of mAb (HSA respectively), no
defined new band in higher molecular weight ranges was
seen (Fig. 2); however a smear in the range of 50–65 kDa (150–
160 kDa in the case of the reference not containing HSA) was
Table 1 LC-MS/MS analysis of mAb-HSA conjugates. HSA and mAb were cross-linked with tyrosinase in the presence of CA. The SDS-PAGE band at y216 kDa was
subjected to tryptic digestion followed by LC-MS/MS analysis. The table shows the most abundant peptides found in a NCBI protein database search
Group
(#)
MS/MS
Spectra (#)
Distinct
peptides (#)
Sequence
coverage (%)
Protein
MW (Da) Species Protein name
1 148 24 49 69 367 Homo Sapiens Serum albumin preprotein
2 119 10 27 51 973 Mus musculus IgG protein
Fig. 2 Left: HSA-FITC fluorescence scan; right: Kang staining of SDS PAGE gradient gel (6% lower and 5.5% upper part) showing the blanks of cross-linking of mAb
and HSA by tyrosinase in combination with different phenolic molecules. Lanes 1–6 show references where mAb was replaced by reaction buffer, lanes 8–13 show
references where HSA was replaced by reaction buffer.
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visible (Fig. 2 lanes 1,2 and 8,9). This indicated that these
phenolic molecules are not only acting as a single linker
molecule but also oligomerize after oxidation by AbT. Higher
molecular weight bands of HSA in presence of CA/pCA and AbT
can be explained by this theory, which result from the
attachment of different amounts of CA/pCA oligomers to the
protein (Fig. 2). Oligomerisation of phenolics was also seen in
size exclusion chromatography (SEC) (Fig. 3, elution volume of
6–7 mL). For T even larger products are visible which is most
likely due to eumelanin production, since T is a natural
substrate for tyrosinase which is converted to the polymer
melanin during melanogenesis in insects, animal and
plants.25 Only for CA and pCA a different peak pattern in the
elution volume range of 7–10 mL is visible which is correlated
to the mAb-HSA conjugate.
A reaction mechanism for the enzymatic cross-linking of
mAb and HSA is hypothesized (Fig. 4). In a first step, the
phenolic compound is oxidized to the corresponding quinone.
Subsequently, either mAb or HSA can bind through amino- or
sulfhydryl groups. In the next step, the phenolic moiety is re-
oxidized and eventually further phenolic molecules attach.
Finally, coupling of mAb-(CA)n and HSA-(CA)m lead to the
corresponding conjugates.
Binding characteristics of the enzymatically conjugated mAb
The mAb used in this study recognizes a common epitope on
the beta-chain of human HLA-DR and HLA-DP.26 DR and DP
are isotypes of the human MHC class II molecule, which is
found on antigen-presenting cells like macrophages, dendritic
cells or B cells. The MHC class II molecule consists of two
polypeptide chains (alpha and beta), which are sub-structured
into two subdomains respectively (alpha 1 and alpha 2, beta 1
and beta 2). A small antigenic peptide can be bound in the
region between alpha 1 and beta 1 and be presented to CD4-
positive T cells.27
ELISA and flow cytometry analysis were performed to study
the impact of enzymatic cross-linking and conjugation with
HSA on the binding characteristics of the anti-MHC class II
mAb. Both tests are based on the comparison of the binding
pattern of the HSA-mAb conjugate and the free mAb to MHC
class II molecules. Prior to ELISA and flow cytometry, the mAb-
HSA conjugate (cross-linked by CA) was purified using SEC
and fractions of peak III were pooled (Fig. 5, inlet). First, the
binding ability of the mAb-HSA conjugate was tested by ELISA.
As shown in Fig. 5, the binding of the mAb-HSA conjugate to
the MHC class II molecules in lysate of MHC II positive Raji B
cells was similar to the binding of the free mAb. Presence of
HSA in the conjugate was proved by detection with 1) LC-MS/
MS and 2) and anti-HSA antibody. The signal of the HSA-mAb
was one third higher than when incubated with secondary
antibody only showing the presence of HSA. In contrast, no
signal enhancement was visible when only free mAb was used
in the primary incubation. Further we conclude from this
experiment, that no unspecific binding of reference samples,
including free HSA, isotype antibody and blocking buffer, to
MHC class II molecules is detectable.
Second, by flow cytometry analysis we tested the binding of
the mAb-HSA conjugate to MHC class II molecules on living
cells by employing MHC class II positive Raji B cells and MHC
class II negative Jurkat T cells. Interestingly, the binding
pattern of mAb-HSA was similar to the binding pattern of free
mAb (Fig. 6) indicating that the HSA-conjugated mAb
recognized its antigen well. However, the conjugates displayed
also weak reactivity with the MHC class II negative cells. This
might be due to the induction of a slight unspecificity upon
AbT-mediated conjugation that might be controlled by
optimization of the coupling conditions. Alternatively, the
conjugation could also increase the affinity of the anti-MHC
class II mAb revealing a weak expression of its epitope on
Jurkat T cells.
Experimental
Materials
Tyrosinase from Agaricus bisporus (AbT) was purchased from
Sigma-Aldrich (Steinheim, Germany). The activity was mea-
sured with an adapted method from Robb28 and calculated to
be 2.41 U mL21 where one unit represents the amount of
enzyme, which converts 1 mmol of L-tyrosine to L-dopaquinone.
Human serum albumin (HSA) and fluorescein 5(6)-isothiocya-
nate (FITC) were purchased from Sigma-Aldrich (Steinheim,
Germany). Mouse monoclonal antibody (mAb) to HLA-DR+DP
(MEM-136, IgG1), mouse IgG1 isotype control mAb (MOPC-21)
and mouse mAb to human serum albumin (AL-01 (IgG1)) were
a kind gift from EXBIO Praha, a.s. (Vestec, Czech Republic).
Mouse mAb to alpha-fetoprotein that was used as an isotype
control in flow cytometry experiments (AFP-12, IgG1) was a
kind gift from Dr Va´clav Horˇejsˇı´ (Institute of Molecular
Genetics, Academy of Sciences of the Czech Republic,
Prague, Czech Republic). Allophycocyanin (APC)-conjugated
goat anti-mouse IgG+IgM antibody was purchased from
Jackson ImmunoResearch, West Grove, PA, USA and anti-
mouse IgG-HRP conjugate from Amersham. ECLTM Western
Blotting System was purchased from GE-Healthcare (Vienna,
Austria). All other reagents used were of analytical grade.
Methods
Cross-linking reaction. For enzymatic cross-linking, stock
solutions of all proteins were freshly prepared in 0.1 M sodium
phosphate buffer (pH 6.8) in following concentrations: mAb
4.7 mg mL21, HSA-FITC 10 mg mL21 and AbT 1.0 mg mL21.
HSA was covalently labeled with FITC prior to the cross-
linking experiment. Therefore 4 mL of a HSA solution (10 mg
mL21 in 50 mM bicarbonate buffer, pH 9.0) were mixed with
200 mL of FITC solution (5 mg mL21 in DMSO). This mixture
was shaken for four hours at 25 uC under light protection.
Thereafter the mixture was purified by size exclusion
chromatography using a HiPrep 26/10 Desalting column (GE
Healthcare Europe GmbH, Vienna, Austria) installed on a A¨kta
Purifier system (Amersham Pharmacia Biotech, Uppsala,
Sweden), with 50 mM potassium phosphate and 100 mM
NaCl (pH 7.4) as eluent, at the flow rate of 3 mL min21 to
remove excess FITC. Fractions showing absorbance at 280 and
485 nm were collected and reduced to a volume of 4 mL using
a Vivaspin 30kD centrifugal separator at 5000 rpm using
Biofuge primo (Heraeus, Buckinghamshire, England).
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Fig. 4 Suggested reaction scheme for tyrosinase induced cross-linking of mAb and HSA. In a first step, phenolic cross-linkers (exemplary shown for CA) containing
hydroxyl- and acrylic acid groups are oxidized by tyrosinase to give the corresponding reactive quinones. In the next step, these quinones couple to –NH2 or –SH
residues of mAb and/or HSA. These adducts can either cross-link directly or after incorporation of further phenolic cross-linkers (as indicated by enlarged bands in
SDS-PAGE analysis). Right: possible conjugates being generated during enzymatic cross-linking process of mAb and HSA, including predicted molecular weights.
Fig. 3 SEC analysis of enzymatic cross-linking products of mAb and HSA cross-linked with AbT in the presence of different phenolic molecules (2 mM CA, pCA, G, FA, C
and 1 mM T).
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Fig. 5 ELISA to compare the binding properties of enzymatically cross-linked mAb-HSA conjugate. Lysates of MHC class II positive Raji B cells were analyzed with
fraction III of SEC in comparison to free mAb, free HSA, isotype control mAb AFP-12 and blocking buffer alone. Binding was detected by incubation with an anti-HSA
antibody followed by incubation with a horseradish peroxidase-labeled secondary antibody. Control incubation was performed with the secondary antibody only.
Inlet: SEC of enzymatic mAb-HSA coupling using 2 mM CA as phenolic linker molecule. Products were eluted using a low flow rate of 0.2 mL min21, fractions of peak
III were collected and concentrated.
Fig. 6 Flow cytometry analysis of MHC class II positive Raji B cells and MHC class II negative Jurkat T cells to compare the binding properties of mAb-HSA conjugates
(FITC-labeled and non-labeled), unconjugated FITC-labeled HSA and unconjugated anti-MHC class II mAb MEM-136. The binding was visualized using APC-labeled
secondary antibody to mouse Ig (y axis). The fluorescence intensity of FITC is shown on the x axis of the two-dimensional dot plot diagrams. Numbers represent
percentage of cells in the quadrants in comparison to the isotype control mAb AFP-12 that was set to a cut-off of 0.1%. Images are representative of three
independent experiments.
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Six different phenolic molecules (caffeic acid (CA), p-cou-
maric acid (pCA), guiacol (G), ferulic acid (FA), catechol (C) and
tyrosine (T)) were tested for their linker ability. Therefore they
were dissolved in 50% EtOH in H2O to a concentration of 30
mM (tyrosine 2 mM).
For the cross-linking experiment mAb (6.0 mM) was
combined with the double molar amount of HSA (12.0 mM)
and 2 mM of each phenolic linker molecule (1 mM for
tyrosine) in a total reaction volume of 100 mL. The reaction was
started by adding AbT in the dosage of 0.55 U mL21. For all
cross-linking experiments reference samples were prepared by
replacing HSA, phenolic molecules, mAb, and AbT, respectively
with reaction buffer. All samples were shaken at 450 rpm at a
temperature of 25 uC for 24 h.
Analysis
Size exclusion chromatography (SEC). For product analysis
SEC was performed using a Superdex 200 10/300 GL (GE
Healthcare Europe GmbH, Vienna, Austria) installed on an
A¨kta Purifier system (Amersham Pharmacia Biotech, Uppsala,
Sweden). 0.1 M NaPh buffer (pH 6.8) was used as eluent, at a
flow rate of 0.4 mL min21, and absorbance was detected at 280
nm.
For product purification the centrifuged crude mixture was
desalted using a 5 mL HiTrapTM column (GE Healthcare
Europe GmbH, Vienna, Austria) at a flow rate of 1 mL min21,
followed by SEC using a Superdex 200 10/300 GL with a lower
flow rate of 0.2 mL min21. Proteins within one peak were
pooled and concentrated using a Vivaspin 2.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS PAGE). SDS PAGE was performed using a Tris-HCl
gradient gel (6% lower–5.5% upper part). For molecular weight
determination a high range protein standard (Spectra
Multicolor High Range Protein Ladder, Fermentas) was used.
The proteins were visualized with Coomassie Blue staining
according to Kang.29 FITC labeled HSA was detected by
fluorescent scanning (Ex. 488 nm, Em. 530 nm) of gels on a
molecular imager equipped with Laser Scanner FXPro and
analysed by Quantity One software (Bio-Rad).
Liquid chromatography–mass spectrometry (LC-MS/MS)
analysis. Protein identification and internal sequence infor-
mation was received from LC-MS/MS. The protein product
band stained with Coomassie Brillant Blue R-250 was excised
from the SDS gel and reduced, alkylated and digested with
Promega modified trypsin according to the method of
Shevchenko et al.30
Digests were separated by nano-HPLC (Agilent 1200 system,
Vienna, Austria) equipped with a Zorbax 300SB-C18 enrich-
ment column (5 mm, 5 6 0.3 mm) and a Zorbax 300SB-C18
nanocolumn (3.5 mm, 150 6 0.075 mm). 40 mL of sample was
injected and concentrated on the enrichment column for 6
min using 0.1% formic acid as isocratic solvent at a flow rate
of 20 mL min21. The column was then switched in the
nanoflow circuit, and the sample was loaded on the
nanocolumn at a flow rate of 300 nL min21. Separation was
carried out using the following gradient, where solvent A is
0.3% formic acid in water and solvent B is a mixture of
acetonitrile and water (4 : 1, by vol.) containing 0.3% formic
acid: 0–6 min: 13% B; 6–35 min: 13–28% B; 35–47 min: 28–
50% B, 47–48 min: 50–100% B; 48–58 min: 100% B; 58–59 min:
100–13% B; 59–70 min: re-equilibration at 13% B. The sample
was ionized in the nanospray source equipped with nanospray
tips (PicoTipTM Stock# FS360-75-15-D-20, Coating: 1P-4P, 15¡
1 mm Emitter, New Objective, Woburn, MA, USA). It was
analysed in a Thermo LTQ-FT mass spectrometer (Thermo
Fisher Scientific, Waltham, MA, USA) operated in positive ion
mode, applying alternating full scan MS (m/z 400 to 2000) in
the ion cyclotron and MS/MS by collision induced dissociation
of the 5 most intense peaks in the ion trap with dynamic
exclusion enabled.
The LC-MS/MS data were analysed by searching the NCBI
public database downloaded on Aug 23rd, 2011 with Spectrum
mill Rev. A.03.03.084 SR4 (Agilent, Vienna, Austria). Detailed
search criteria for Spectrum Mill were: trypsin; max. missed
cleavage sites: 2; carbamidomethylation at cysteine as fixed
modification; variable modification: oxidised methionine;
precursor mass tolerance ¡ 0.05 Da; product mass tolerance
¡ 0.7 Da. Protein hits were subjected to automatic validation
by Spectrum mill: for precursor charge of 2: score threshold
6.0, percent scored peak intensity (%SPI) threshold 60.0, Fwd-
Rev score threshold 2.0 and rank 1–2 score threshold 2.0; for
precursor charge of 1: score threshold 6.0, %SPI threshold
70.0, Fwd-Rev score threshold 2.0 and rank 1–2 score thresh-
old 2.0; for precursor charge of 3: score threshold 8.0, %SPI
threshold 70.0, Fwd-Rev score threshold 2.0 and rank 1–2
score threshold 2.0.
Antibody function
Cells. The Jurkat T cell line E6.1 and the B cell line Raji were
purchased from the American Type Culture Collection. Cells
were maintained in RPMI 1640 medium supplemented with 2
mM L-glutamine, 50 mg mL21 streptomycin, and 50 U mL21
penicillin and 10% heat inactivated FCS (all from Invitrogen)
in a humidified atmosphere with 5% CO2 at 37 uC.
Enzyme-linked immunosorbent assay (ELISA). To compare
the binding of the mAb-HSA conjugate to that of the free mAb
an ELISA was performed. Wells of ELISA plates (Greiner high
and medium binding 96 well plates, Sigma-Aldrich, Steinheim,
Germany) were coated with 50 mL of Raji cell lysate (1 6 105
cells mL21) for 12 h. Cell lysate was obtained by centrifuging
10 6 106 cells at 350 g, whereas the supernatant was
discarded, and the cell pellet resolved in 100 mL lysis buffer
containing 20 mM Na2HPO4, 1% detergent TritonX100 and 1x
protease inhibitor cocktail (Roche) at pH 7.4. After washing
with washing buffer (0.05% detergent Tween 20 in PBS, pH
7.4) and blocking (1% skimmed dry milk in washing buffer)
the mAb-HSA conjugate and control samples (buffer, free mAb,
AFP12 isotype control mAb, free HSA) were incubated for 1 h at
23 uC. After washing, the samples were incubated for 1 h with
an anti-HSA antibody followed by incubation with a horse-
radish peroxidase-labeled secondary antibody. A control
incubation was performed where the samples were incubated
with the secondary antibody only. The immune-reaction was
visualized using o-phenylenediamine as a substrate (Sigma-
Aldrich). The reaction was stopped by the addition of 3 M HCl
and optical density was read in a microplate reader at 492 nm.
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Flow cytometry. Cells were washed with staining buffer (PBS
containing 1% BSA and 0.02% NaN3) and incubated for 30 min
with 4.8 mg mL21 human IgG on ice to prevent nonspecific
binding of the mAbs to Fc receptors. Then, the FITC-labeled
mAb-HSA conjugate, the non-labeled one, the free primary
mAb, the free FITC-conjugated HSA or the isotype control mAb
AFP-12 (all 10 mg mL21) was added and the cells were
incubated for 30 min on ice. Cells were washed with staining
buffer and incubated with APC-conjugated secondary antibody
for 30 min on ice. After a final wash, cells were analyzed on an
LSRII flow cytometer (BD Biosciences) and the data further
processed with the FloJo software (Treestar). The live cells were
gated according to their forward- and side-scatter character-
istics and exclusion of dead cells using DAPI.
Conclusion
The enzymatic synthesis of mAb-HSA conjugates suitable for
targeted drug delivery devices was investigated. We were able
to demonstrate that the conjugated mAb is still recognizing its
antigen with immunological tests comparing the binding
ability of free mAb and the mAb-HSA conjugate to MHC class
II molecules. The enzyme tyrosinase from Agaricus bisporus
was used to cross-link HSA and mAb in the presence of
phenolic molecules. Out of six phenolic compounds tested, CA
and pCA were able to act as a spacer and cross-linker. We
assume that the acrylic acid moiety in combination with a
mono- or biphenol is the crucial point for a successful cross-
linking reaction. Conjugates were analyzed using SDS-PAGE
and SEC. LC-MS/MS analysis of the peptide fragments,
obtained by a tryptic digest of a product band at the molecular
weight range of y216 kDa, which is the predicted molecular
weight for a mAb-HSA conjugate, confirmed that this product
consist of mAb and HSA. Consequently this one-step enzy-
matic cross-linking strategy not only represents a green
alternative for conventional laborious methods but also avoids
expensive and harmful chemical cross-linkers.
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